GlassScriptPhysician profile
Roshanda Washington
NPI 1205500261
$1,531.87
in general payments reported to CMS, 2019-2025
13 companies · $765 in 2025
The $765 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $83.23 · 2023: $232 · 2024: $318 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.25 | 2021-2025 | |
| Axsome Therapeutics, INC. | $288.18 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $276.38 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.45 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.08 | 2024 | Jardiance |
| Tris Pharma INC | $83.80 | 2024-2025 | Dyanavel Xr |
| Lilly USA, LLC | $59.91 | 2023-2025 | Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $57.40 | 2025 | Rexulti |
| Novo Nordisk INC | $33.28 | 2024 | Ozempic, Rybelsus |
| Alkermes, INC. | $19.72 | 2023 | Vivitrol |
| Vanda Pharmaceuticals INC. | $16.77 | 2024 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $16.25 | 2024 | Voquezna |
| Organon LLC | $8.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshanda Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.